Blue Jet Healthcare Ltd
BLUEJET NSE
Blue Jet Healthcare Ltd
HealthcareNSE: BLUEJET BSE: 544009 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹11,516 Cr
Volatility
Moderate
P/E Ratio
44.82
EBITDA
₹215 Cr
Return on Equity
39.96%
Debt to Equity
0.03
Book Value
₹114.11
EPS
₹9.47
52W High
₹792
52W Low
₹325
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Blue Jet Healthcare Ltd insights
42 extracted metrics + investor summaries across FY20–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
2- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 24.0%
Weaknesses
2- Stock is trading at 7.75 times its book value
- Working capital days have increased from 158 days to 224 days
Growth Rate
Revenue Growth
-6.62% ↘
Net Income Growth
-6.34% ↘
Cash Flow Change
5.34% ↗
ROE
-44.11% ↘
ROCE
-38.82% ↘
EBITDA Margin (Avg.)
4.83% ↘
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 15d agoAI opinion · based on fundamentals
Risk high
Blue Jet Healthcare is an almost debt-free specialty pharma intermediates company with a market cap of ~₹12,000 Cr trading at a PE of 47.9x. Revenue declined 8% on a TTM basis and net profit fell 17% YoY (FY26 PAT ₹248 Cr vs ₹305 Cr in FY25), though the company maintains a 3-year ROE of 24% and is investing ₹2,300 Cr in a greenfield facility for future growth.
Bull Case 8
- Almost debt-free balance sheet provides financial flexibility and low interest burden (interest cost just ₹6.2 Cr in FY26 on ₹332 Cr EBITDA)
- Strong 3-year ROE track record of 24% and 5-year ROE of 26%, indicating efficient capital deployment
- Contrast Media intermediates revenue grew 23% YoY in FY26 to ₹495 Cr, demonstrating diversification strength
- Q4 FY25 EBITDA margins climbed to 41%, up 1,190 bps YoY, showing operating leverage potential
- Compounded sales CAGR of 14% over 5 years reflects solid medium-term topline growth trajectory
- ₹2,300 Cr greenfield facility in Andhra Pradesh positions the company for CDMO and capacity expansion
- Gross margins improved to 54.9% in Q4 FY25, up 160 bps YoY, indicating better product mix
- Compounded profit CAGR of 16% over 3 years despite recent cyclical downturn
Bear Case 8
- TTM revenue declined 8% and FY26 revenue fell to ₹947 Cr from ₹1,030 Cr in FY25, indicating demand softness
- Net profit dropped 17% on TTM basis — FY26 PAT of ₹248 Cr vs ₹305 Cr in FY25
- Stock trades at 7.99x book value and 47.9x PE, demanding premium valuation despite earnings decline
- Working capital days increased sharply from 158 days to 224 days, signaling cash conversion deterioration
- Stock price declined 21% over the past 1 year, reflecting market skepticism on near-term growth
- Q1 FY27 revenue fell 17.7% YoY with profit down 14.2%, suggesting the downturn is continuing
- Planned ₹1,000 Cr QIP fundraise may dilute existing shareholders during a period of weak earnings
- Dividend yield of just 0.19% offers negligible income support at current valuation levels
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 15d ago Headwinds 2
- FY26 net profit drops 18.8% Jul 6
Full-year net profit fell 18.8% to ₹2,478.16 million for FY26, with revenue declining 7.9% to ₹9,423.67 million.
- Q1FY27 profit down 14.2% YoY Aug 3
Q1FY27 net profit came in at ₹782.64 million, down 14.2% YoY, with revenue falling to ₹2,931.13 million.
Positives 2
- EcoVadis Silver Medal won Jul 20
Blue Jet awarded EcoVadis Silver Medal for sustainability with a score of 77, placing it in the top 15% globally.
- ₹1.2 interim dividend approved Aug 3
Board approved an interim dividend of ₹1.2 per share alongside Q1FY27 results announcement.
Neutral 3
- QIP opened at ₹531.70 floor Jul 6
Qualified Institutions Placement opened on July 6, 2026, with a floor price of ₹531.70 per share following Board and shareholder approvals.
- Promoter confirms no encumbrance Jul 27
Akshay Bansarilal Arora and PACs confirmed zero encumbrance on their 79.81% stake per SEBI Regulation 31(4) annual disclosure for FY26.
- Q1FY27 earnings call scheduled Jul 28
Analyst and investor conference call scheduled for August 3, 2026, at 5:30 PM IST to discuss Q1FY27 unaudited standalone results.
TL;DR: Blue Jet Healthcare is facing a clear earnings deterioration trend with both FY26 and Q1FY27 showing double-digit profit declines alongside falling revenues. The QIP at ₹531.70 suggests capital-raising needs, while the EcoVadis recognition and clean promoter holding structure are modest positives. The revenue contraction trend across multiple quarters is the key risk to monitor. Until top-line growth resumes, the earnings trajectory remains under pressure.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 180 | 181 | 167 | 184 | 163 | 208 | 318 | 340 | 355 | 165 | 192 | 235 | 293 |
| Expenses | 121 | 119 | 112 | 131 | 119 | 139 | 194 | 200 | 234 | 111 | 146 | 163 | 195 |
| Operating Profit | 59 | 63 | 55 | 53 | 44 | 69 | 124 | 140 | 121 | 55 | 47 | 71 | 98 |
| OPM % | 33% | 35% | 33% | 29% | 27% | 33% | 39% | 41% | 34% | 33% | 24% | 30% | 33% |
| Other Income | 5 | 8 | -3 | 9 | 9 | 12 | 13 | 12 | 8 | 24 | 13 | 23 | 15 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 0 | 1 | 1 |
| Depreciation | 6 | 6 | 8 | 8 | 3 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 7 |
| PBT | 58 | 64 | 44 | 54 | 49 | 77 | 132 | 147 | 123 | 69 | 54 | 87 | 106 |
| Tax % | 24% | 26% | 27% | 27% | 24% | 24% | 25% | 25% | 26% | 24% | 25% | 26% | 26% |
| Net Profit | 44 | 48 | 32 | 40 | 38 | 58 | 99 | 110 | 91 | 52 | 40 | 64 | 78 |
| EPS in Rs | 2.54 | 2.76 | 1.85 | 2.29 | 2.18 | 3.36 | 5.71 | 6.35 | 5.26 | 3.01 | 2.32 | 3.71 | 4.51 |
Profit & Loss
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 538 | 499 | 683 | 721 | 712 | 1,030 | 947 | 886 |
| Expenses | 325 | 292 | 434 | 502 | 481 | 652 | 653 | 614 |
| Operating Profit | 214 | 207 | 249 | 219 | 231 | 378 | 294 | 271 |
| OPM % | 40% | 41% | 36% | 30% | 32% | 37% | 31% | 31% |
| Other Income | 6 | 9 | 19 | 24 | 18 | 46 | 69 | 76 |
| Interest | 7 | 5 | 3 | 1 | 0 | 0 | 6 | 6 |
| Depreciation | 18 | 20 | 22 | 25 | 28 | 18 | 24 | 25 |
| PBT | 194 | 190 | 243 | 217 | 220 | 406 | 333 | 316 |
| Tax % | 25% | 26% | 25% | 26% | 26% | 25% | 25% | — |
| Net Profit | 145 | 142 | 182 | 160 | 164 | 305 | 248 | 235 |
| EPS in Rs | 24,118 | 1,429 | 10.47 | 9.23 | 9.44 | 17.59 | 14.29 | 13.55 |
| Div. Payout % | 0% | 0% | 0% | 0% | 11% | 7% | 8% | — |
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.6 | 10 | 35 | 35 | 35 | 35 | 35 |
| Reserves | 198 | 330 | 487 | 647 | 811 | 1,098 | 1,325 |
| Borrowings | 74 | 52 | 19 | 5 | 3 | 21 | 42 |
| Other Liabilities | 92 | 142 | 173 | 176 | 211 | 263 | 239 |
| Total Liabilities | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,641 |
| Fixed Assets | 107 | 139 | 156 | 151 | 172 | 300 | 316 |
| CWIP | 2 | 3 | 3 | 30 | 147 | 89 | 301 |
| Investments | 26 | 37 | 94 | 189 | 250 | 187 | 252 |
| Other Assets | 229 | 355 | 460 | 491 | 489 | 841 | 771 |
| Total Assets | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,641 |
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Operating | 122 | 137 | 146 | 142 | 241 | 46 | 334 |
| Investing | -45 | -61 | -76 | -147 | -264 | -35 | -276 |
| Financing | -72 | -21 | -56 | -4 | -2 | -19 | -31 |
| Net Cash Flow | 5 | 55 | 14 | -10 | -24 | -8 | 28 |
| Free Cash Flow | 106 | 85 | 125 | 83 | 68 | -34 | 115 |
| CFO/OP | 80 | 66 | 70 | 92 | 109 | 36 | 151 |
Ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 105 | 121 | 121 | 91 | 124 | 131 |
| Inventory Days | 120 | 253 | 133 | 137 | 151 | 209 | 157 |
| Days Payable | 90 | 128 | 72 | 58 | 35 | 70 | 48 |
| Cash Conversion Cycle | 110 | 231 | 183 | 199 | 206 | 262 | 240 |
| Working Capital Days | 55 | 89 | 103 | 120 | 92 | 157 | 224 |
| ROCE % | — | 58% | 53% | 35% | 30% | 40% | 26% |
Documents
1
Notice Of The 58Th Annual General Meeting Of Blue Jet Healthcare Limited
18 Aug - 58th AGM on Sept 21, 2026; ₹1.20 dividend, auditor and director reappointments proposed. 18 Aug - 58th AGM on Sept 21, 2026; ₹1.20 dividend, auditor and director reappointments proposed.
2
Business Responsibility and Sustainability Reporting (BRSR)
18 Aug - Blue Jet Healthcare filed its FY2025-26 Business Responsibility and Sustainability Report on August 18, 2026. 18 Aug - Blue Jet Healthcare filed its FY2025-26 Business Responsibility and Sustainability Report on August 18, 2026.
3
Clarification sought from Blue Jet Healthcare Ltd
12 Jun - Exchange has sought clarification from Blue Jet Healthcare Ltd on June 12, 2026, with reference to Movement in Volume. 12 Jun - Exchange has sought clarification from Blue Jet Healthcare Ltd on June 12, 2026, with reference to Movement in Volume.
5
Closure of Trading Window
24 Mar - Trading window closed from April 1, 2026 until 48 hours after audited FY2025-26 results. 24 Mar - Trading window closed from April 1, 2026 until 48 hours after audited FY2025-26 results.
Frequently Asked Questions about Blue Jet Healthcare Ltd
What does Blue Jet Healthcare Ltd do?
Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India.[1]
Where is Blue Jet Healthcare Ltd (BLUEJET) listed?
Blue Jet Healthcare Ltd is listed on the Indian stock exchanges. It is listed on NSE: BLUEJET and BSE: 544009. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Blue Jet Healthcare Ltd belong to?
Blue Jet Healthcare Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Blue Jet Healthcare Ltd?
Blue Jet Healthcare Ltd has a market capitalisation of approximately ₹11515.53 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Blue Jet Healthcare Ltd?
The Price-to-Earnings (PE) ratio of Blue Jet Healthcare Ltd is 44.82. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Blue Jet Healthcare Ltd?
Over the past 52 weeks, Blue Jet Healthcare Ltd has traded between a low of ₹325 and a high of ₹792. This range helps investors understand the stock's price volatility and recent trading levels.
Does Blue Jet Healthcare Ltd pay dividends?
Yes, Blue Jet Healthcare Ltd has a dividend yield of 0.20%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Blue Jet Healthcare Ltd?
Blue Jet Healthcare Ltd has a Return on Equity (ROE) of 39.96%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Blue Jet Healthcare Ltd on Tapetide?
On Tapetide, you can view Blue Jet Healthcare Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India.[1]
Website bluejethealthcare.com
CEO Mr. Akshay Bansarilal Arora
Employees 196
Listed 2023-11-01
Face Value ₹ 2
Issued Size 17,34,65,425